Internal Medicine Alert – August 30, 2003
August 30, 2003
View Issues
-
Fibbers
Only about 12% of patients with new onset atrial fibrillation who did not have apparent contraindications to warfarin treatment filled prescriptions for it. -
A Visit to a Dangerous PAD
Peripheral arterial disease is common. Screening with measurement of the ankle-brachial index will improve detection. -
The Skinny On Low-Fat and Low-Carbohydrate Diets
The low-carbohydrate diet produced a greater weight loss than did the conventional diet for the first 6 months, but the differences were not significant at 1 year. -
SAH Risk May Be Reduced By Healthy Lifestyle
The association of caffeine and nicotine in pharmaceutical products and aneurysmal SAH warrants further study. -
Reduced Cardiac Risk for Breast Cancer Survivors
Women who survive breast cancer may be at a lower risk of developing coronary artery disease compared with women without a history of breast cancer. -
Pharmacology Update: Atazanavir Sulfate Capsules (Reyataz)
The FDA has approved the first once-daily protease inhibitor (PI) for the treatment of HIV-1 infections. Atazanavir (Bristol-Myers Squibb) is the newest PI to enter this relatively crowded class. It is marketed under the trade name Reyataz. -
Clinical Briefs
A Strategy to Reduce Cardiovascular Disease by More Than 80 Percent; Pearly Penile Papules: Still No Reason for Uneasiness; The Epidemiology of Major Depressive Disorder